Characteristics of responders vs nonresponders by treatment group
| Variable . | HCVAD, N = 35 . | SL401, N = 37 . | Other, N = 28 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Responders, n = 28 . | Nonresponders, n = 7 . | P . | Responders, n = 22 . | Nonresponders, n = 15 . | P . | Responders, n = 12 . | Nonresponders n=16 . | P . | |
| Sex | |||||||||
| Male | 28 (100) | 5 (71) | .004 | 15 (68) | 12 (80) | .43 | 9 (75) | 12 (75) | 1 |
| Female | 0 | 2 (29) | 7 (32) | 3 (20) | 3 (25) | 4 (25) | |||
| Age at Dx, median (range), y | 56 (20-77) | 67 (56-86) | .07 | 68 (22-84) | 74 (21-82) | .57 | 58 (14-77) | 70 (32-86) | .06 |
| WBC at Dx, median (range), ×109/L | 6 (1.7-24.3) | 26.2 (1.9-76.5) | .03 | 5.9 (1.9-10.2) | 4.9 (2-56.8) | .57 | 6.9 (1.5 −179) | 5.4 (1.7 −14.2) | .52 |
| Hgb at Dx, median (range), g/dL | 13.3 (6.8-17) | 12 (7.2-15.9) | .39 | 13.7 (8.3-17) | 12.6 (9.4-15.5) | .51 | 11.6 (8-15.7) | 11.6 (7.7 −17.1) | .88 |
| Plt at Dx, median (range), ×109/L | 140 (18-325) | 142 (11-365) | .45 | 177 (61-396) | 117 (39-407) | .02 | 111 (22-260) | 157 (53-273) | .26 |
| LDH, U/L at Dx, median (range), n = 30 | 508 (121-799) | 712 (191- 4108) | .57 | 533 (164-811) | 516 (164-1800) | .72 | NA | 386 (266-505) | |
| BM Bl at Dx, median (range), % | 4 (0-95) | 18 (1.2-54) | .65 | 3 (0-94) | 26 (1-92) | .15 | 23 (0-86) | 13.5 (0-77) | .91 |
| Involvement of BPDCN disease | |||||||||
| Bone marrow | 21 (75) | 4 (57) | .35 | 15 (68) | 11 (73) | .74 | 11 (92) | 10 (63) | .08 |
| Skin | 20 (71) | 7 (100) | .11 | 20 (91) | 14 (93) | .79 | 6 (50) | 12 (75) | .17 |
| Lymph node | 12 (43) | 2 (29) | .49 | 5 (23) | 1 (7) | .19 | 1 (8) | 3 (19) | .44 |
| Cytogenetics | |||||||||
| Complex cytogenetics | 7 (25) | 3 (43) | .71 | 4 (18) | 2 (13) | .61 | 2 (17) | 2 (13) | .92 |
| Diploid cytogenetics | 13 (46) | 4 (57) | 16 (27) | 13 (87) | 8 (67) | 9 (56) | |||
| Mutations | |||||||||
| TET2 | 5/10 (50) | 2/3 (67) | .61 | 17/21 (81) | 11/14 (79) | .86 | 6/7 (86) | 6/6 (100) | .34 |
| ASXL1 | 4/10 (40) | 0/3 (0) | .19 | 7/21 (33) | 5/14 (36) | .88 | 2/7 (29) | 4/6 (67) | .17 |
| RAS | 1/11 (9) | 1/3 (33) | .23 | 1/21 (5) | 3/14 (21) | .13 | 2/7 (29) | 3/8 (38) | .71 |
| CR, n | 28 | 0 | 22 | 0 | 12 | 0 | |||
| HSCT | 17 (61) | 1 (14) | .03 | 14 (64) | 3 (20) | .01 | 7 (58) | 3 (19) | .001 |
| HSCT in CR1 | 15 (54) | 0 | .01 | 13 (59) | 0 | 0 | 4 (33) | 0 | .01 |
| Days to Rx1, median (range) | 27 (0-108) | 28 (15-95) | 44 (0-84) | 56 (10-112) | 7 (0-421) | 50 (3-337) | |||
| Male | 27 (0-108) | 27 (15-95) | 40 (0-57) | 59 (12-112) | 7 (0-421) | 56 (3-337) | |||
| Female | NA | 46 (28-64) | 49 (11-84) | 22 (10-66) | 6 (5-83) | 22 (19-26) | |||
| Dx/Rx1 with skin only | 6 (21) | 3 (43) | 9 (41) | 6 (40) | 2 (17) | 7 (44) | |||
| Days to Rx1, median (range) | 36 (8-83) | 53 (26-95) | 48 (7-84) | 68 (18-101) | 50 (5-94) | 63 (20-337) | |||
| Variable . | HCVAD, N = 35 . | SL401, N = 37 . | Other, N = 28 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Responders, n = 28 . | Nonresponders, n = 7 . | P . | Responders, n = 22 . | Nonresponders, n = 15 . | P . | Responders, n = 12 . | Nonresponders n=16 . | P . | |
| Sex | |||||||||
| Male | 28 (100) | 5 (71) | .004 | 15 (68) | 12 (80) | .43 | 9 (75) | 12 (75) | 1 |
| Female | 0 | 2 (29) | 7 (32) | 3 (20) | 3 (25) | 4 (25) | |||
| Age at Dx, median (range), y | 56 (20-77) | 67 (56-86) | .07 | 68 (22-84) | 74 (21-82) | .57 | 58 (14-77) | 70 (32-86) | .06 |
| WBC at Dx, median (range), ×109/L | 6 (1.7-24.3) | 26.2 (1.9-76.5) | .03 | 5.9 (1.9-10.2) | 4.9 (2-56.8) | .57 | 6.9 (1.5 −179) | 5.4 (1.7 −14.2) | .52 |
| Hgb at Dx, median (range), g/dL | 13.3 (6.8-17) | 12 (7.2-15.9) | .39 | 13.7 (8.3-17) | 12.6 (9.4-15.5) | .51 | 11.6 (8-15.7) | 11.6 (7.7 −17.1) | .88 |
| Plt at Dx, median (range), ×109/L | 140 (18-325) | 142 (11-365) | .45 | 177 (61-396) | 117 (39-407) | .02 | 111 (22-260) | 157 (53-273) | .26 |
| LDH, U/L at Dx, median (range), n = 30 | 508 (121-799) | 712 (191- 4108) | .57 | 533 (164-811) | 516 (164-1800) | .72 | NA | 386 (266-505) | |
| BM Bl at Dx, median (range), % | 4 (0-95) | 18 (1.2-54) | .65 | 3 (0-94) | 26 (1-92) | .15 | 23 (0-86) | 13.5 (0-77) | .91 |
| Involvement of BPDCN disease | |||||||||
| Bone marrow | 21 (75) | 4 (57) | .35 | 15 (68) | 11 (73) | .74 | 11 (92) | 10 (63) | .08 |
| Skin | 20 (71) | 7 (100) | .11 | 20 (91) | 14 (93) | .79 | 6 (50) | 12 (75) | .17 |
| Lymph node | 12 (43) | 2 (29) | .49 | 5 (23) | 1 (7) | .19 | 1 (8) | 3 (19) | .44 |
| Cytogenetics | |||||||||
| Complex cytogenetics | 7 (25) | 3 (43) | .71 | 4 (18) | 2 (13) | .61 | 2 (17) | 2 (13) | .92 |
| Diploid cytogenetics | 13 (46) | 4 (57) | 16 (27) | 13 (87) | 8 (67) | 9 (56) | |||
| Mutations | |||||||||
| TET2 | 5/10 (50) | 2/3 (67) | .61 | 17/21 (81) | 11/14 (79) | .86 | 6/7 (86) | 6/6 (100) | .34 |
| ASXL1 | 4/10 (40) | 0/3 (0) | .19 | 7/21 (33) | 5/14 (36) | .88 | 2/7 (29) | 4/6 (67) | .17 |
| RAS | 1/11 (9) | 1/3 (33) | .23 | 1/21 (5) | 3/14 (21) | .13 | 2/7 (29) | 3/8 (38) | .71 |
| CR, n | 28 | 0 | 22 | 0 | 12 | 0 | |||
| HSCT | 17 (61) | 1 (14) | .03 | 14 (64) | 3 (20) | .01 | 7 (58) | 3 (19) | .001 |
| HSCT in CR1 | 15 (54) | 0 | .01 | 13 (59) | 0 | 0 | 4 (33) | 0 | .01 |
| Days to Rx1, median (range) | 27 (0-108) | 28 (15-95) | 44 (0-84) | 56 (10-112) | 7 (0-421) | 50 (3-337) | |||
| Male | 27 (0-108) | 27 (15-95) | 40 (0-57) | 59 (12-112) | 7 (0-421) | 56 (3-337) | |||
| Female | NA | 46 (28-64) | 49 (11-84) | 22 (10-66) | 6 (5-83) | 22 (19-26) | |||
| Dx/Rx1 with skin only | 6 (21) | 3 (43) | 9 (41) | 6 (40) | 2 (17) | 7 (44) | |||
| Days to Rx1, median (range) | 36 (8-83) | 53 (26-95) | 48 (7-84) | 68 (18-101) | 50 (5-94) | 63 (20-337) | |||
Unless otherwise noted, data are n (%).
BM Bl, bone marrow blast; Dx, diagnosis; Hgb, hemoglobin; LDH, lactate dehydrogenase; NA, not applicable; Plt, platelet; Rx1, first treatment; WBC, white blood cell.
P values in bold denote statistical significance.